多发性-话题@MedSci

#多发性#

905篇内容 | 3039人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1890066, encodeId=6e901890066d9, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=NCCN临床实践指南：多发性骨髓瘤（2020.V1）, objectType=article, longId=180233, objectId=289b18023346, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=289b18023346, replyNumber=0, likeNumber=16, createdTime=2020-05-16, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=289b18023346, moduleTitle=NCCN临床实践指南：多发性骨髓瘤（2020.V1）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=289b18023346)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890093, encodeId=d0a3189009331, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, objectType=article, longId=188065, objectId=7e7c18806539, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e7c18806539, replyNumber=0, likeNumber=68, createdTime=2020-12-27, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e7c18806539, moduleTitle=强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e7c18806539)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890061, encodeId=5f5a1890061ff, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Glenmark双特异性抗体GBR 1342治疗多发性骨髓瘤，喜获FDA孤儿药物指定, objectType=article, longId=179623, objectId=75b91e96234a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75b91e96234a, replyNumber=0, likeNumber=79, createdTime=2020-07-15, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75b91e96234a, moduleTitle=Glenmark双特异性抗体GBR 1342治疗多发性骨髓瘤，喜获FDA孤儿药物指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75b91e96234a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890140, encodeId=9fd118901409d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤, objectType=article, longId=197722, objectId=54d019e7223c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54d019e7223c, replyNumber=0, likeNumber=72, createdTime=2021-03-05, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54d019e7223c, moduleTitle=Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54d019e7223c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890149, encodeId=4752189014933, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Blood：与多发性骨髓瘤来那度胺或泊马度胺获得性耐药相关的CBRN变异, objectType=article, longId=199253, objectId=e69319925396, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e69319925396, replyNumber=0, likeNumber=0, createdTime=2021-01-15, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e69319925396, moduleTitle=Blood：与多发性骨髓瘤来那度胺或泊马度胺获得性耐药相关的CBRN变异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e69319925396)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890116, encodeId=b5ee1890116a0, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=FDA批准Banner的BAFIERTAM（富马酸单甲酯），用于治疗多发性硬化症, objectType=article, longId=193382, objectId=b2ed193382f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2ed193382f9, replyNumber=0, likeNumber=93, createdTime=2021-03-15, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2ed193382f9, moduleTitle=FDA批准Banner的BAFIERTAM（富马酸单甲酯），用于治疗多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2ed193382f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890104, encodeId=823d18901048b, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症, objectType=article, longId=190924, objectId=13da19092498, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13da19092498, replyNumber=0, likeNumber=92, createdTime=2021-03-09, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13da19092498, moduleTitle=百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13da19092498)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890137, encodeId=9683189013ebc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=慢性炎症性脱髓鞘性多发性神经根神经病1例, objectType=article, longId=197442, objectId=cc7019e44253, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc7019e44253, replyNumber=0, likeNumber=103, createdTime=2020-08-02, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc7019e44253, moduleTitle=慢性炎症性脱髓鞘性多发性神经根神经病1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc7019e44253)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890049, encodeId=f02e1890049ae, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究, objectType=article, longId=178110, objectId=262c1e81109b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=262c1e81109b, replyNumber=0, likeNumber=58, createdTime=2019-09-24, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=262c1e81109b, moduleTitle=NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=262c1e81109b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890079, encodeId=e9de18900e966, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=多发性硬化症极易误诊，身体出现这些症状需要注意啦！, objectType=article, longId=184352, objectId=962d18435259, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=962d18435259, replyNumber=0, likeNumber=67, createdTime=2020-10-20, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=962d18435259, moduleTitle=多发性硬化症极易误诊，身体出现这些症状需要注意啦！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=962d18435259)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890050, encodeId=8dd61890050cd, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点, objectType=article, longId=178211, objectId=25671e8211a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25671e8211a0, replyNumber=0, likeNumber=51, createdTime=2019-12-21, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25671e8211a0, moduleTitle=抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25671e8211a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890065, encodeId=498c18900659d, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, objectType=article, longId=180138, objectId=16d3180138ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d3180138ee, replyNumber=0, likeNumber=58, createdTime=2019-10-31, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d3180138ee, moduleTitle=美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d3180138ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890120, encodeId=5152189012003, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=JAMA Neurol:多发性硬化患者需警惕心脑血管疾病风险, objectType=article, longId=193617, objectId=d16c19361e47, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16c19361e47, replyNumber=0, likeNumber=0, createdTime=2020-05-15, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16c19361e47, moduleTitle=JAMA Neurol:多发性硬化患者需警惕心脑血管疾病风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16c19361e47)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890062, encodeId=01091890062db, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=科济生物CT053全人抗BCMA-CAR T细胞治疗复发/难治多发性骨髓瘤临床研究结果令人鼓舞, objectType=article, longId=179638, objectId=933c1e9638de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=933c1e9638de, replyNumber=0, likeNumber=83, createdTime=2019-11-01, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=933c1e9638de, moduleTitle=科济生物CT053全人抗BCMA-CAR T细胞治疗复发/难治多发性骨髓瘤临床研究结果令人鼓舞, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=933c1e9638de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890051, encodeId=d07f1890051d9, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=欧盟批准elotuzumab联合泊马度胺和低剂量地塞米松（EPd）治疗复发和难治性多发性骨髓瘤, objectType=article, longId=178293, objectId=b7be1e8293c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7be1e8293c3, replyNumber=0, likeNumber=75, createdTime=2020-02-25, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7be1e8293c3, moduleTitle=欧盟批准elotuzumab联合泊马度胺和低剂量地塞米松（EPd）治疗复发和难治性多发性骨髓瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7be1e8293c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890097, encodeId=adfd189009e47, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, objectType=article, longId=189451, objectId=9d821894518e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d821894518e, replyNumber=0, likeNumber=92, createdTime=2020-04-29, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d821894518e, moduleTitle=Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d821894518e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890060, encodeId=f34e1890060bc, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=第17届IMW：GRIFFIN研究揭示daratumumab一线治疗多发性骨髓瘤具有高反应率和反应深度, objectType=article, longId=179541, objectId=713e1e9541a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=713e1e9541a0, replyNumber=0, likeNumber=69, createdTime=2020-01-20, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=713e1e9541a0, moduleTitle=第17届IMW：GRIFFIN研究揭示daratumumab一线治疗多发性骨髓瘤具有高反应率和反应深度, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=713e1e9541a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890042, encodeId=ea98189004220, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, objectType=article, longId=176219, objectId=d8491e621960, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8491e621960, replyNumber=0, likeNumber=57, createdTime=2019-07-26, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8491e621960, moduleTitle=Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8491e621960)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890082, encodeId=9bf618900820c, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=股骨头坏死并发多发性滑膜软骨瘤1例, objectType=article, longId=185092, objectId=b02318509273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b02318509273, replyNumber=0, likeNumber=87, createdTime=2020-03-10, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b02318509273, moduleTitle=股骨头坏死并发多发性滑膜软骨瘤1例, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b02318509273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1890125, encodeId=0649189012530, content=<a href='/topic/show?id=760c430895a' target=_blank style='color:#2F92EE;'>#多发性#</a>, objectTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, objectType=article, longId=194711, objectId=2e1a194e1115, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e1a194e1115, replyNumber=0, likeNumber=0, createdTime=2020-08-12, rootId=0, userName=jml2009, userId=04d6114, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e1a194e1115, moduleTitle=EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e1a194e1115)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

多发性

2020-05-29

jml2009 (审核中...)

前往app查看评论内容

#多发性#

NCCN临床实践指南：多发性骨髓瘤（2020.V1）

2020-05-16

hb2008ye (审核中...)

前往app查看评论内容

#多发性#

强生向FDA提交申请，将其抗CD38单抗Darzalex与Kyprolis和地塞米松联合治疗多发性骨髓瘤

2020-12-27

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Glenmark双特异性抗体GBR 1342治疗多发性骨髓瘤，喜获FDA孤儿药物指定

2020-07-15

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Lancet：卡非佐米、达雷木单抗联合地塞米松治疗复发或难治性多发性骨髓瘤

2021-03-05

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Blood：与多发性骨髓瘤来那度胺或泊马度胺获得性耐药相关的CBRN变异

2021-01-15

jml2009 (审核中...)

前往app查看评论内容

#多发性#

FDA批准Banner的BAFIERTAM（富马酸单甲酯），用于治疗多发性硬化症

2021-03-15

智慧医人 (审核中...)

前往app查看评论内容

#多发性#

百时美施贵宝的1-磷酸鞘氨醇受体调节剂ozanimod，获FDA批准治疗复发型多发性硬化症

2021-03-09

jml2009 (审核中...)

前往app查看评论内容

#多发性#

慢性炎症性脱髓鞘性多发性神经根神经病1例

2020-08-02

jml2009 (审核中...)

前往app查看评论内容

#多发性#

NEJM：XPOVIO（Selinexor）治疗难治性多发性骨髓瘤的IIb期STORM研究

2019-09-24

jml2009 (审核中...)

前往app查看评论内容

#多发性#

多发性硬化症极易误诊，身体出现这些症状需要注意啦！

2020-10-20

jml2009 (审核中...)

前往app查看评论内容

#多发性#

抗BCMA药物belantamab mafodotin治疗多发性骨髓瘤的关键研究达到主要终点

2019-12-21

jml2009 (审核中...)

前往app查看评论内容

#多发性#

美国FDA批准CD38单抗Darzalex联合疗法，用于可移植的多发性骨髓瘤

2019-10-31

jml2009 (审核中...)

前往app查看评论内容

#多发性#

JAMA Neurol:多发性硬化患者需警惕心脑血管疾病风险

2020-05-15

jml2009 (审核中...)

前往app查看评论内容

#多发性#

科济生物CT053全人抗BCMA-CAR T细胞治疗复发/难治多发性骨髓瘤临床研究结果令人鼓舞

2019-11-01

jml2009 (审核中...)

前往app查看评论内容

#多发性#

欧盟批准elotuzumab联合泊马度胺和低剂量地塞米松（EPd）治疗复发和难治性多发性骨髓瘤

2020-02-25

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Karyopharm的口服核出口选择性抑制剂XPOVIO针对多发性骨髓瘤的III期临床试验达到终点

2020-04-29

jml2009 (审核中...)

前往app查看评论内容

#多发性#

第17届IMW：GRIFFIN研究揭示daratumumab一线治疗多发性骨髓瘤具有高反应率和反应深度

2020-01-20

jml2009 (审核中...)

前往app查看评论内容

#多发性#

Ponesimod治疗复发性多发性硬化症的III期研究结果：符合其主要和次要终点

2019-07-26

jml2009 (审核中...)

前往app查看评论内容

#多发性#

股骨头坏死并发多发性滑膜软骨瘤1例

2020-03-10

jml2009 (审核中...)

前往app查看评论内容

#多发性#

EAN 2020：BTK抑制剂Evobrutinib治疗复发性多发性硬化症的有效性和安全性良好

2020-08-12

科室
- - 订阅+
  - 更多科室
工具
服务